Download PDF
Thromb Haemost 1990; 64(03): 369-373
DOI: 10.1055/s-0038-1647321
Original Article
Schattauer GmbH Stuttgart

A Specific Thromboxane Receptor Blocking Drug, AH23848, Reduces Platelet Deposition on Vascular Grafts in Man

I F Lane
The Department of Surgery, Charing Cross Hospital, London
,
P Lumley
1   Glaxo Group Research Ltd, Ware, Hertfordshire, U. K.
,
M F Michael
1   Glaxo Group Research Ltd, Ware, Hertfordshire, U. K.
,
A M Peters
1   Glaxo Group Research Ltd, Ware, Hertfordshire, U. K.
,
C N McCollum
The Department of Surgery, Charing Cross Hospital, London
› Author Affiliations
Further Information

Publication History

Received: 23 November 1989

Accepted after revision23 May 1990

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The antithrombotic effect of a specific thromboxane A2 receptor blocking drug, AH23848, on radio-labelled platelet deposition in mature Dacron aorto-bifemoral grafts has been evaluated in patients. Thirty patients were randomly allocated to AH23848 70 mg, aspirin 300 mg plus dipyridamole 75 mg or placebo 8-hourly for 9 days. AH23848 inhibited platelet aggregarion induced by the thromboxane ,A2 mimetic U-46619; no such effect was observed with aspirin plus dipyridamole. 111In-platelet uptake was measured as the thrombogenicity index (TI) which is a measure of the daily rate of accumulation of platelets by the graft. The mean (s.e. mean) value of 0.193 (0.029) on placebo was significantly reduced to 0.115 (0.022) by AH23848 (p <0.05) but only to 0.175 (0.028) by aspirin plus dipyridamole. There was no difference in mean platelet life span between the three treatment groups. The pronounced antithrombotic effect of AH23848 implicates thromboxane ,A2 in the process of platelet deposition in arterial prostheses and demonstrates the considerable promise of thromboxane receptor blocking drugs as antithrombotic therapy.

 

  • References

  • 1 Baumgartner HR, Muggli R. Adhesion and aggregation: morphological demonstration and quantitation in vivo and in vitro. In: Platelets in Biology and Pathology Gordon JL. ed Elsevier/North-Holland Biomedical Press; Amsterdam: 1976: 23-60
  • 2 Menys VC, Davies JA. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion. Thromb Haemostas 1983; 49: 96-101
    PubMedGoogle Scholar
  • 3 Salzman EW, Lindon J, Brier D, Merrill EW. Surface-induced platelet adhesion, aggregation and release. Ann NY Acad Sci 1977; 283: 114-27
    CrossrefPubMedGoogle Scholar
  • 4 Kester RC. The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs. Ann Coll Surg Engl 1984; 66: 241-6
    PubMedGoogle Scholar
  • 5 Goldman M, Hall C, Hawker RJ, McCollum CN. Dazoxiben examined for platelet inhibitory effect in an artificial circulation. Br J Clin Pharmacol 1983; 15: 615-55
    PubMedGoogle Scholar
  • 6 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
    CrossrefPubMedGoogle Scholar
  • 7 Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 1976; 261: 558-560
    CrossrefPubMedGoogle Scholar
  • 8 Bhagwat SS, Hamann PR, Still WC, Bunting S, Fitzpatrick FA. Synthesis and structure of the platelet aggregation factor thromboxane A2 . Nature 1985; 315: 511-3
    CrossrefPubMedGoogle Scholar
  • 9 Weiss HJ, Tschopp TB, Baumgartner HR. Impaired interaction (adhesion-aggregation) of platelets with the subendothelium in storage- pool disease and after aspirin ingestion. N Engl J Med 1985; 293: 619-23
    PubMedGoogle Scholar
  • 10 Tschopp TB. Aspirin inhibits platelet aggregation on, but not adhesion to, collagen fibrils: An assessment of platelet adhesion and deposited platelet mass by morphometry and 51Cr-labelling. Thromb Res 1977; 11: 619-42
    CrossrefPubMedGoogle Scholar
  • 11 Baumgartner HR, Muggli R. Effect of acetylsalicyclic acid on platelet adhesion to subendothelium and on mural thrombus formation in vitro and in vivo. Stroke 1974; 5: 297
    PubMedGoogle Scholar
  • 12 Wu KK, Chen Y-C, Fordham E, Ts’ao C-H. Differential effects of two doses of aspirin on platelet vessel wall interaction in vivo. J Clin Invest 1981; 68: 382-7
    CrossrefPubMedGoogle Scholar
  • 13 McCollum CN, Crow MJ, Rajah SM, Kester RC. Antithrombotic therapy for vascular prosthesis: An experimental model testing platelet inhibitory drugs. Surgery 1980; 87: 668-676
    PubMedGoogle Scholar
  • 14 Dewanjee MK, Pumphrey CW, Murphy KP, Rosemark JA, Chesebro JH, Fuster VD, Kaye MP. Evaluation of platelet-inhibitor drugs in a canine bilateral femoral graft implant model. Tians Arn Soc Artif Intern Organs 1982; 28: 504-9
    PubMedGoogle Scholar
  • 15 Green RM, Roedersheimer LR, De Weese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery 1982; 92: 1016-1026
    PubMedGoogle Scholar
  • 16 Oblath RW, Buckley FO, Green RM, Schwartz SI, De Weese JA. Prevention of platelet aggregation and adherence to prosthetic vascular grafts by aspirin and dipyridamole. Surgery 1978; 84: 37-45
    PubMedGoogle Scholar
  • 17 Goldman MD, Simpson D, Hawker RJ, Norcott HC, McCollum CN. Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal grafts in man. Ann Surg 1983; 198: 713-716
    CrossrefPubMedGoogle Scholar
  • 18 Pumphrey Cw, Chesebro JH, Dewanjee MK, Wahner HW, Hollier LH, Pairolero PC, Fuster V. In vivo quantitation of platelet deposition on human peripheral arterial bypass grafts using indium-111-labelled platelets: effects of dipyridamole and aspirin. Am J Cardiol 1983; 51: 796-801
    CrossrefPubMedGoogle Scholar
  • 19 Paris Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980; 62: 449-61
    PubMedGoogle Scholar
  • 20 Humphrey PP A, Lumley P. The effects of AH23848, a novel thromboxane receptor blocking drug, on platelets and vascular smooth muscle. Br J Pharmacol Proc Suppl 1984; 83: 378P
    PubMedGoogle Scholar
  • 21 Brittain RT, Coleman RA, Collington EW, Hallet P, Humphrey PP A, Kennedy I, Lumley P, Sheldrick RL G, Wallis CJ. AH23848: A potent, selective thromboxane receptor blocking drug on smooth muscle. Br J Pharmacol Proc Suppl 1984; 83: 377P
    PubMedGoogle Scholar
  • 22 Brittain RT, Boutal L, Carter MC, Coleman RA, Collington Ew, Geisow HP, Hallet P, Hornby EJ, Humphrey PP A, Jack D, Kennedy I, Lumley R, McCabe PJ, Skidmore IE, Thomas M, Wallis CJ. AH23848: A thromboxane receptor blocking drug which can clarify the pathophysiological role of thromboxane A2 . Circulation 1985; 72: 1208-18
    CrossrefPubMedGoogle Scholar
  • 23 Coleman RA, Humphrey PP A, Kennedy I, Levy GP, Lumley P. Corirparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane ,A2 on some isolated smooth muscle preparations. Br J Pharmacol 1981; 73: 773-778
    CrossrefPubMedGoogle Scholar
  • 24 Boutal LE, Foster MR, Geisow HP, Skidmore IE. Inhibition of 111-indium labelled platelet deposition by aspirin, prostacyclin and the thromboxane antagonist, AH23U8. Br J Pharmacol Proc Suppl 1985; 86: 802P
    PubMedGoogle Scholar
  • 25 Thomas M, Lumley p, Hornby EJ. A study to investigate the effects of a novel thromboxane receptor blocking drug AH23848 on platelet aggregation ex vivo in man. Br J Clin Pharmacol 1985; 19: l23P-4P
    PubMedGoogle Scholar
  • 26 Thomas M, Lumley P, Fowler R. Effect of repeat dosing with the thrornboxane receptor blocking drug AH23848 on platelet aggregation ex vivo in man. Br J Clin Pharmacol 1985; 20: 543P-4P
    PubMedGoogle Scholar
  • 27 Ritchie JL, Stratton JR, Thiele B, Hamilton GW, Warrick LN, Huang TW, Harker LA. Indium-111 platelet imaging for detection of platelet deposition in abdominal aneurysms and prosthetic grafts. Am J Cardiol 1981; 47: 882-889
    CrossrefPubMedGoogle Scholar
  • 28 Goldmatr M, Norcott HC, Hawker RJ, Hail C, Drolc Z, McCollum CN. Femoropopliteal bypass grafts - an isotope technique allowing in vivo comparison of thrombogenicity. Br J Surg 1982; 69: 3802
    PubMedGoogle Scholar
  • 29 Stratton JR, Thiele BL, Ritchie JL. Platelet deposition on Dacron aortic bifurcation grafts in man: Quantitation with indium-l11 platelet imaging. Circulation 1982; 66: 1287-93
    CrossrefPubMedGoogle Scholar
  • 30 Norcott HC, Goldman M, Hawker RJ, Rafiqi EI, Drolc Z, McCollum CN. Platelet inhibitory drugs: an in vivo method of evaluation in patients. Thromb Haemostas 1982; 48: 307-10
    PubMedGoogle Scholar
  • 31 Goldmatr M, Hall C, Dykes J, Hawker RJ, McCollum CN. Does 111-Indium labelled platelet deposition predict patency in prosthetic arterial grafts. Br J Surg 1983; 70: 635-8
    CrossrefPubMedGoogle Scholar
  • 32 Goldmatr M, Norcott HC, Hawker RJ, Drolc Z, McCollum CN. Platelet accumulation on mature Dacron grafts in man. Br J Surg 1982; 69 Suppl S38-S40
    CrossrefPubMedGoogle Scholar
  • 33 Stratton JR, Thiele BL, Ritchie JL. Natural history of platelet deposition on dacron aortic bifurcation grafts in the first year after implantation. Am J Cardiol 1983; 52: 371-4
    CrossrefPubMedGoogle Scholar
  • 34 Lumley P, Humphrey PP A. A method for quantitating platelet aggregation and analysing drug-receptor interactions on platelets in whole blood in vitro. J Pharmacol Methods 1981; 6: 153-66
    CrossrefPubMedGoogle Scholar
  • 35 Hawker RJ, Hawker LM, wilkinson AR. Indium (111In) labelled human platelets: optimal method. Clin Sci 1980; 58: 243-8
    CrossrefPubMedGoogle Scholar
  • 36 Murphy EA, Francis ME. The estimation of blood platelet survival. II. The multiple hit model. Thromb Haemostas 1971 25. 53-80
    PubMedGoogle Scholar
  • 37 Lane IE, Irwin JT C, White B, McCollum CN. pseudointima in PTFE grafts reduced by a specific thromboxane Az antagonist. Proceedings of XVII World Congress of the International Society for Cardiovascular Surgery, Monte Carlo 1985
    PubMedGoogle Scholar
  • 38 Sinzinger H, Silberbauer K, Winter M, Auerswald w. Implanted vascular prostheses generate prostacyclin. Lancet 1978; ii: 840
    PubMedGoogle Scholar
  • 39 Stratton JR, Ritchie JL. Reduction of indium-111 platelet deposition on Dacron vascular grafts in humans by aspirin plus dipyridamole. Circulation 1986; 73: 325-30
    CrossrefPubMedGoogle Scholar
  • 40 Kidson IG, Stoney DW, Tibb DJ, Morris PJ. Expanded polytetrafluoroethylene grafts for severe lower limb ischaemia. Br J Surg 1981; 68: 173-7
    CrossrefPubMedGoogle Scholar
  • 41 Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley wI, Frye RL, Holmes Jr DR, Mietstra RE, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Schaff HV, Danielson GK. A platelet-inhibitor-drug trial in coronary-artery bypass operations. Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 1982 307. 73-78
    PubMedGoogle Scholar
  • 2 Chesebro JH, Fuster v, Elveback LR, Clements IP, Smith HC, Holmes DR, Bardsley W, Pluth JR, Wallace RB, Puga FJ, Orszulak RA, Piehler JM, Danielson GK, Schaff HV, Frye RL. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984; 310: 209-214
    CrossrefPubMedGoogle Scholar
  • 43 Lumley P, white BP, Humphrey PP A. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airway smooth muscle in vitro. Br J Pharmacol 1989; 97: 783-94
    CrossrefPubMedGoogle Scholar
  • 44 Lumley R, Humphrey PP A, white BP. GR32191, a novel thromboxane receptor blocking drug: effects upon platelets and vascular and airway smooth muscle in vivo. Br J Pharmacol Proc Suppl 1988; 93: 43P
    PubMedGoogle Scholar
  • 45 Thomas M, Lumley p, Ballard P, O’Brien JR. Initial studies in man with a novel thromboxane receptor blocking drug GR32191. Thromb Haemostas 1987; 58: 181
    PubMedGoogle Scholar
  • 46 De Bono DP, Lumley P, Been M, Keery R, Ince S, Woodings DE. The effect of the specific thromboxane receptor blocking drug, AH23848 in patients with angina pectoris. Br Heart J 1986; 56: 509-17
    CrossrefPubMedGoogle Scholar